GenE Phase 3 Clinical Trial
Chefaro is conducting GenE (DAL-301), the first interventional precision medicine cardiovascular outcomes trial. This Phase 3 clinical trial is evaluating the efficacy of dalcetrapib versus placebo to reduce clinical cardiovascular events in 6,149 patients who have experienced an -Acute Coronary Syndrome (ACS) who carry the ADCY9 rs1967309 AA genotype. The trial aims to reduce major adverse cardiovascular events (MACE). The GenE Trial is fully recruited, passed a futility analysis in January 2020, and trial completion is expected in the first half of 2021.
For more information about the GenE study, please visit clinicaltrials.gov and access NCT02525939.
